UBS Group AG Has $15.15 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX

UBS Group AG grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 648,987 shares of the biopharmaceutical company’s stock after buying an additional 55,378 shares during the quarter. UBS Group AG’s holdings in Catalyst Pharmaceuticals were worth $15,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. lifted its stake in shares of Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after acquiring an additional 2,095,291 shares during the period. American Century Companies Inc. lifted its stake in Catalyst Pharmaceuticals by 43.8% in the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after buying an additional 770,198 shares during the period. Fundsmith LLP lifted its stake in Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after buying an additional 654,721 shares during the period. Glenmede Investment Management LP lifted its stake in Catalyst Pharmaceuticals by 781.8% in the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock valued at $13,400,000 after buying an additional 603,084 shares during the period. Finally, Bank of America Corp DE lifted its stake in Catalyst Pharmaceuticals by 30.6% in the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after buying an additional 554,200 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on CPRX. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Finally, Zacks Research raised Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.17.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.16 on Thursday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The business has a 50-day moving average of $25.86 and a two-hundred day moving average of $24.21. The company has a market capitalization of $3.81 billion, a P/E ratio of 17.91, a price-to-earnings-growth ratio of 0.91 and a beta of 0.72.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).